MA56504A - Dérivés de pyridin-3-yle - Google Patents
Dérivés de pyridin-3-yleInfo
- Publication number
- MA56504A MA56504A MA056504A MA56504A MA56504A MA 56504 A MA56504 A MA 56504A MA 056504 A MA056504 A MA 056504A MA 56504 A MA56504 A MA 56504A MA 56504 A MA56504 A MA 56504A
- Authority
- MA
- Morocco
- Prior art keywords
- yle
- pyridin
- derivatives
- yle derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Debugging And Monitoring (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019065963 | 2019-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56504A true MA56504A (fr) | 2022-04-27 |
Family
ID=71105482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056504A MA56504A (fr) | 2019-06-18 | 2020-06-17 | Dérivés de pyridin-3-yle |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12479820B2 (fr) |
| EP (1) | EP3986884A1 (fr) |
| JP (1) | JP7494222B2 (fr) |
| KR (1) | KR102786045B1 (fr) |
| CN (1) | CN114026082B (fr) |
| AR (1) | AR119162A1 (fr) |
| AU (1) | AU2020298014B2 (fr) |
| BR (1) | BR112021025236A2 (fr) |
| CA (1) | CA3143618A1 (fr) |
| CL (1) | CL2021003348A1 (fr) |
| IL (1) | IL288950B2 (fr) |
| MA (1) | MA56504A (fr) |
| MX (1) | MX2021015727A (fr) |
| PH (1) | PH12021553178A1 (fr) |
| SG (1) | SG11202111162PA (fr) |
| TW (1) | TWI845708B (fr) |
| UA (1) | UA130692C2 (fr) |
| WO (1) | WO2020254408A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3802517T (lt) | 2018-06-07 | 2023-03-10 | Idorsia Pharmaceuticals Ltd | Alkoksi-pakeistieji piridinilo dariniai kaip lpa1 receptoriaus antagonistai ir jų panaudojimas fibrozės gydymui |
| CN114761001A (zh) * | 2019-12-04 | 2022-07-15 | 爱杜西亚药品有限公司 | 氮杂环丁烷lpa1受体拮抗剂与抗纤维化药剂的组合 |
| WO2025169931A1 (fr) * | 2024-02-05 | 2025-08-14 | Ｕｂｅ株式会社 | Composé carboxamide |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL262366A (fr) | 1960-03-14 | |||
| WO1994006802A1 (fr) * | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation medicinale |
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| WO2001032173A1 (fr) | 1999-10-29 | 2001-05-10 | Yamanouchi Pharmaceutical Co., Ltd. | Inhibiteurs de neurocytotoxicite de l'acide kainique |
| AU2001262185A1 (en) | 2000-04-10 | 2001-10-23 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
| EP1364659B1 (fr) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US7435824B2 (en) | 2002-04-19 | 2008-10-14 | Bristol-Myers Squibb Company | Prodrugs of potassium channel inhibitors |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| EP1628666B1 (fr) | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Composes et leurs utilisations pour la modulation de l'amyloide-beta |
| MXPA06002853A (es) | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
| US20070078120A1 (en) | 2003-10-21 | 2007-04-05 | Hitoshi Ban | Novel piperidine derivative |
| US20070105902A1 (en) | 2003-11-12 | 2007-05-10 | Lindsley Craig W | 4-Phenyl piperdine sulfonyl glycine transporter inhibitors |
| JP2007511597A (ja) | 2003-11-18 | 2007-05-10 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 抗菌アミノキナゾリヂンヂオン誘導体 |
| WO2006091862A2 (fr) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Inhibiteurs des cytokines et utilisation therapeutique |
| PL1889836T3 (pl) | 2005-08-24 | 2013-10-31 | Eisai R&D Man Co Ltd | Nowa pochodna pirydyny i pochodna pirymidyny (3) |
| WO2007058990A2 (fr) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapie a base d’inhibiteurs de cytokine |
| CA2691214A1 (fr) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapie a base d'inhibiteurs de cytokine |
| JP5164510B2 (ja) | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
| US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| CA2700648A1 (fr) | 2007-10-18 | 2009-04-23 | Merck Sharp & Dohme Corp. | Modulateurs allosteriques positifs du recepteur m1 de la quinolizidinone |
| EP2297153B1 (fr) | 2008-04-21 | 2015-05-27 | Lexicon Pharmaceuticals, Inc. | Inhibiteurs de limk2, compositions les comprenant et leurs procédés d'utilisation |
| LT2303270T (lt) | 2008-05-05 | 2017-09-11 | Sanofi | Acilamino-pakeistieji sulieti ciklopentankarboksirūgšties dariniai ir jų panaudojimas kaip vaistų |
| KR20110045019A (ko) | 2008-08-26 | 2011-05-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물을 위한 티에노피리미딘 |
| RU2609021C2 (ru) * | 2009-09-25 | 2017-01-30 | Астеллас Фарма Инк. | Замещенные соединения амида |
| CN103270036B (zh) | 2010-08-05 | 2015-11-25 | 佐蒂斯有限责任公司 | 作为抗寄生物剂的异噁唑啉衍生物 |
| TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為ｍＰＧＥＳ－１抑制物的三環化合物 |
| CN103596566B (zh) | 2010-12-07 | 2017-08-25 | 阿米拉制药公司 | 多环lpa1拮抗剂及其使用 |
| EP2651930B1 (fr) | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Inhibiteurs biarylamide de production de leukotriènes |
| SI2683723T1 (sl) | 2011-03-10 | 2016-07-29 | Zoetis Services Llc | Spirociklični izoksazolinski derivati kot antiparazitiki |
| EP2794576A1 (fr) | 2011-12-21 | 2014-10-29 | Ardelyx, Inc. | Agonistes de tgr5 non systémiques |
| US20140148484A1 (en) | 2012-11-23 | 2014-05-29 | Boehringer Ingelheim International Gmbh | Pyrazole compounds for treating hairloss |
| TW201444820A (zh) * | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| KR102292433B1 (ko) | 2013-11-06 | 2021-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | Gsk-3 억제제로서 유용한 치환된 피리딘 유도체 |
| AR108185A1 (es) | 2016-04-06 | 2018-07-25 | Abbvie Inc | Amidas terciarias y método para su uso |
| LT3802517T (lt) * | 2018-06-07 | 2023-03-10 | Idorsia Pharmaceuticals Ltd | Alkoksi-pakeistieji piridinilo dariniai kaip lpa1 receptoriaus antagonistai ir jų panaudojimas fibrozės gydymui |
| CN114761001A (zh) | 2019-12-04 | 2022-07-15 | 爱杜西亚药品有限公司 | 氮杂环丁烷lpa1受体拮抗剂与抗纤维化药剂的组合 |
-
2020
- 2020-06-16 AR ARP200101686A patent/AR119162A1/es unknown
- 2020-06-17 UA UAA202107611A patent/UA130692C2/uk unknown
- 2020-06-17 TW TW109120315A patent/TWI845708B/zh active
- 2020-06-17 CN CN202080044333.8A patent/CN114026082B/zh active Active
- 2020-06-17 CA CA3143618A patent/CA3143618A1/fr active Pending
- 2020-06-17 KR KR1020227001133A patent/KR102786045B1/ko active Active
- 2020-06-17 JP JP2021574814A patent/JP7494222B2/ja active Active
- 2020-06-17 PH PH1/2021/553178A patent/PH12021553178A1/en unknown
- 2020-06-17 MA MA056504A patent/MA56504A/fr unknown
- 2020-06-17 EP EP20733601.7A patent/EP3986884A1/fr active Pending
- 2020-06-17 SG SG11202111162PA patent/SG11202111162PA/en unknown
- 2020-06-17 BR BR112021025236A patent/BR112021025236A2/pt unknown
- 2020-06-17 MX MX2021015727A patent/MX2021015727A/es unknown
- 2020-06-17 WO PCT/EP2020/066767 patent/WO2020254408A1/fr not_active Ceased
- 2020-06-17 IL IL288950A patent/IL288950B2/en unknown
- 2020-06-17 US US17/620,520 patent/US12479820B2/en active Active
- 2020-06-17 AU AU2020298014A patent/AU2020298014B2/en active Active
-
2021
- 2021-12-15 CL CL2021003348A patent/CL2021003348A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3986884A1 (fr) | 2022-04-27 |
| CL2021003348A1 (es) | 2022-09-23 |
| PH12021553178A1 (en) | 2022-11-07 |
| TWI845708B (zh) | 2024-06-21 |
| UA130692C2 (uk) | 2026-04-22 |
| AR119162A1 (es) | 2021-12-01 |
| JP7494222B2 (ja) | 2024-06-03 |
| CN114026082A (zh) | 2022-02-08 |
| KR20220020921A (ko) | 2022-02-21 |
| CA3143618A1 (fr) | 2020-12-24 |
| BR112021025236A2 (pt) | 2022-02-01 |
| WO2020254408A1 (fr) | 2020-12-24 |
| AU2020298014A1 (en) | 2022-02-10 |
| US12479820B2 (en) | 2025-11-25 |
| MX2021015727A (es) | 2022-01-24 |
| US20220251068A1 (en) | 2022-08-11 |
| IL288950B1 (en) | 2024-11-01 |
| AU2020298014B2 (en) | 2026-02-05 |
| KR102786045B1 (ko) | 2025-03-24 |
| IL288950A (en) | 2022-02-01 |
| SG11202111162PA (en) | 2021-11-29 |
| TW202115011A (zh) | 2021-04-16 |
| JP2022537177A (ja) | 2022-08-24 |
| IL288950B2 (en) | 2025-03-01 |
| CN114026082B (zh) | 2024-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3958977T (pt) | Derivados de camptotecina | |
| IL292753A (en) | Compounds | |
| IL292161A (en) | New methylquinazolinone derivatives | |
| EP3717479C0 (fr) | Dérivés de thiazole microbiocides | |
| EP4038058A4 (fr) | Dérivés de cannabinoïdes | |
| DK4067344T3 (da) | Cycloalkylurinstofderivat | |
| EP4013751C0 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| LT3830085T (lt) | Deuterinti lanifibranoro dariniai | |
| EP4037676A4 (fr) | Dérivés cannabinoïdes | |
| EP4073033A4 (fr) | Dérivés cannabinoïdes | |
| EP3999490A4 (fr) | Dérivés cannabinoïdes | |
| EP3997095A4 (fr) | Dérivés cannabinoïdes | |
| EP3457851A4 (fr) | Dérivés de sobétirome | |
| EP4077334C0 (fr) | Dérivés furoindazole | |
| EP4021904C0 (fr) | Dérivés d'alpha-d-galactopyranoside | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| EP3885347A4 (fr) | Dérivé de dihydropyrrolopyrazole | |
| PT3796975T (pt) | Derivados de sulfonilaminobenzamida | |
| IL304774A (en) | Enhanced sophorolipid derivatives | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| EP3371163A4 (fr) | Dérivés de pyrrolidine | |
| EP4013441A4 (fr) | Formulations de larazotide | |
| EP3472151A4 (fr) | Dérivés de prolinamide carbocycliques | |
| DK3894410T3 (da) | Substituerede xanthinderivater |